Ptc Therapeutics (PTCT) Gains from Investment Securities (2012 - 2026)

Ptc Therapeutics' Gains from Investment Securities history runs 15 years deep, the most recent figure standing at $17815.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 102.23% year-over-year to $17815.0; the TTM figure through Mar 2026 stood at $17815.0 (up 100.02% YoY), while the FY2025 annual figure was $6.4 million, up 51069.62% from the prior year.
• Gains from Investment Securities was $17815.0 for Q1 2026 at Ptc Therapeutics, down from $37.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $37.0 million in Q4 2025 to a low of -$127.6 million in Q4 2023.
• Historically, Gains from Investment Securities has averaged -$3.1 million across 5 years, with a median of $934735.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities surged 4415.38% in 2022, then tumbled 501.3% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $31.8 million in 2022, then sank by 501.3% to -$127.6 million in 2023, then jumped by 95.19% to -$6.1 million in 2024, then soared by 702.74% to $37.0 million in 2025, then tumbled by 99.95% to $17815.0 in 2026.
• The last three Gains from Investment Securities figures came in at $17815.0 (Q1 2026), $37.0 million (Q4 2025), and -$100000.0 (Q3 2025), per Business Quant data.